HLB제약

047920KOSDAQ자연과학 및 공학 연구개발업

56.8 / 100

Reference Date: 2026-06-10

Financial Score21.5 / 40

News Sentiment20.3 / 25

Momentum3.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 34.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Pharmaceuticals, established in 1998, focuses on specialty pharmaceutical manufacturing, CMO services, and health functional food sales. In 2025, it expanded into pharmaceutical distribution by acquiring 100% of Shinwha Advance, achieving a 2025 revenue of 2.055 trillion KRW with a 34% CAGR over five years. The company leverages its DDS technology for long-acting injectables and diversified growth through its joint health functional food brand 'Kwancheol'.

Number of Employees

185people

Average Salary

54.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

77.87Industry Average 62.703.0Point

Higher than industry avg (caution)

PBR

2.88Industry Average 3.244.0Point

In line with industry avg

ROE

3.79Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

4.72Industry Average 7.315.0Point

Lower than industry avg (good)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲25.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲39.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -5.5% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 3Neutral 0Negative 2Average Sentiment Score 81

Positive
멥스젠, 英임페리얼칼리지런던과 '염증성장질환' 모델 공동개발
HLB제약의 신약 개발 파트너인 멥스젠이 염증성장질환 모델 개발에 성공함으로써 기술적 우위를 확보하고 시장 경쟁력을 강화할 것으로 기대된다.
Negative
HLB제약 유증 후폭풍…주주들 주가급락·지분희석에 "철회하라"
HLB제약의 대규모 유상증자 결정 이후 주가 하락과 주주 가치 희석 우려로 인해 부정적 영향이 지속되고 있다.
Positive
HLB제약, 전립선암 치료제 식약처 허가
HLB제약의 전립선암 치료제 엘비탄디 연질 캡슐의 식약처 허가로 인해 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 10,980Won52-week high 20,90052-week low 10,980

1-month return0.0Point

1m -34.45% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 1Neutral 4Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-06-04
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-05-22
Positive주요사항보고서(유상증자결정)2026-05-13
Neutral증권신고서(지분증권)2026-05-13
Neutral분기보고서 (2026.03)2026-05-13